Nothing Special   »   [go: up one dir, main page]

GB0907065D0 - Anti-apoptotic composition and methods for the treatment of otic disorders - Google Patents

Anti-apoptotic composition and methods for the treatment of otic disorders

Info

Publication number
GB0907065D0
GB0907065D0 GBGB0907065.7A GB0907065A GB0907065D0 GB 0907065 D0 GB0907065 D0 GB 0907065D0 GB 0907065 A GB0907065 A GB 0907065A GB 0907065 D0 GB0907065 D0 GB 0907065D0
Authority
GB
United Kingdom
Prior art keywords
treatment
methods
otic disorders
apoptotic composition
apoptotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB0907065.7A
Other versions
GB2461961A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Otonomy Inc
Original Assignee
University of California
Otonomy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Otonomy Inc filed Critical University of California
Publication of GB0907065D0 publication Critical patent/GB0907065D0/en
Priority to US12/500,486 priority Critical patent/US20100016218A1/en
Priority to CA2730847A priority patent/CA2730847A1/en
Priority to EP09798587.3A priority patent/EP2296632A4/en
Priority to RU2011105257/15A priority patent/RU2493828C2/en
Priority to KR1020117002413A priority patent/KR101390607B1/en
Priority to AU2009271129A priority patent/AU2009271129B2/en
Priority to CN2009801276143A priority patent/CN102099013A/en
Priority to PCT/US2009/050077 priority patent/WO2010008995A2/en
Priority to BRPI0915770A priority patent/BRPI0915770A2/en
Priority to JP2011518801A priority patent/JP5491502B2/en
Priority to MX2011000545A priority patent/MX2011000545A/en
Publication of GB2461961A publication Critical patent/GB2461961A/en
Priority to ZA2010/08861A priority patent/ZA201008861B/en
Priority to IL210553A priority patent/IL210553A0/en
Priority to US15/000,988 priority patent/US20160199446A1/en
Priority to US16/387,320 priority patent/US20190298799A1/en
Priority to IL266471A priority patent/IL266471A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
GB0907065A 2008-07-14 2009-04-24 Sterile anti-apoptotic agent for treatment of ear diseases Withdrawn GB2461961A (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
MX2011000545A MX2011000545A (en) 2008-07-14 2009-07-09 Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders.
BRPI0915770A BRPI0915770A2 (en) 2008-07-14 2009-07-09 controlled release apoptosis modulation composition and methods for treating optimal disorders
JP2011518801A JP5491502B2 (en) 2008-07-14 2009-07-09 Controlled release apoptosis modulating compounds and methods for the treatment of otic disorders
EP09798587.3A EP2296632A4 (en) 2008-07-14 2009-07-09 Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
RU2011105257/15A RU2493828C2 (en) 2008-07-14 2009-07-09 Apoptosis modulating compositions with controlled release and methods of treating ear diseases
KR1020117002413A KR101390607B1 (en) 2008-07-14 2009-07-09 Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
AU2009271129A AU2009271129B2 (en) 2008-07-14 2009-07-09 Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
CN2009801276143A CN102099013A (en) 2008-07-14 2009-07-09 Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
PCT/US2009/050077 WO2010008995A2 (en) 2008-07-14 2009-07-09 Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
US12/500,486 US20100016218A1 (en) 2008-07-14 2009-07-09 Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
CA2730847A CA2730847A1 (en) 2008-07-14 2009-07-09 Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
ZA2010/08861A ZA201008861B (en) 2008-07-14 2010-12-09 Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
IL210553A IL210553A0 (en) 2008-07-14 2011-01-11 Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
US15/000,988 US20160199446A1 (en) 2008-07-14 2016-01-19 Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
US16/387,320 US20190298799A1 (en) 2008-07-14 2019-04-17 Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
IL266471A IL266471A (en) 2008-07-14 2019-05-06 Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8058308P 2008-07-14 2008-07-14
US11051108P 2008-10-31 2008-10-31
US16484109P 2009-03-30 2009-03-30

Publications (2)

Publication Number Publication Date
GB0907065D0 true GB0907065D0 (en) 2009-06-03
GB2461961A GB2461961A (en) 2010-01-27

Family

ID=40774911

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0907065A Withdrawn GB2461961A (en) 2008-07-14 2009-04-24 Sterile anti-apoptotic agent for treatment of ear diseases

Country Status (1)

Country Link
GB (1) GB2461961A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2951905A1 (en) * 2014-06-12 2015-12-17 Orbis Biosciences, Inc. Extended-release drug delivery compositions
WO2019154895A1 (en) * 2018-02-08 2019-08-15 Strekin Ag Gel formulation for preventing or treating hearing loss

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) * 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US7758888B2 (en) * 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
WO2006079055A2 (en) * 2005-01-24 2006-07-27 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
WO2007031098A1 (en) * 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway

Also Published As

Publication number Publication date
GB2461961A (en) 2010-01-27

Similar Documents

Publication Publication Date Title
IL266471A (en) Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
ZA201007482B (en) Controlled release corticosteriod compositions and methods for the treatment of otic disorders
IL258730A (en) Compositions and methods for treatment of microbial disorders
IL210720A0 (en) Controlled release antimicrobial compositions and methods for the treatment of otic disorders
EP2120580A4 (en) Compositions and methods for the treatment of metabolic disorders
EP2170309A4 (en) Methods and compositions for treating disorders
SI2894165T1 (en) Methods and compositions for treating complement-associated disorders
GB201001047D0 (en) Methods and compositions for the treatment of neurological disorders
EP2361089A4 (en) Compositions and methods for the treatment of altered -synuclein function
IL222695A0 (en) Methods, compositions, and kits for the treatment of matrix mineralization disorders
WO2011049960A9 (en) Compositions and methods for the treatment of sinonasal disorders
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
EP2309858A4 (en) Compositions and methods for treating inflammatory disorders
EP2299976A4 (en) Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
GB2461186B (en) Controlled release corticosteroid compositions and methods for the treatment of otic disorders
EP2142566A4 (en) Methods and compositions for the treatment of proliferative diseases
EP2285398A4 (en) Methods and compositions for the treatment of obesity
GB0907065D0 (en) Anti-apoptotic composition and methods for the treatment of otic disorders
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia
IL184620A0 (en) Composition for the treatment of inflammation
AU2007906680A0 (en) Methods and compositions for the treatment of phosphatase-related disorders
GB0907070D0 (en) methods for the treatment of otic disorders comprising glutamate agonists and antagonists
EP2276502A4 (en) Compositions for the prevention and treatment of neuroinjury and methods of use thereof
IL210933A0 (en) Compositions and methods for treating inflammatory disorders

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)